Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flu Vaccine Strains Get Easy OK From FDA Panel, But Desire For More Efficacy Remains

Executive Summary

US advisory committee overwhelmingly supports WHO's influenza vaccine strain selections, although data are limited as to why current vaccines are not more effective. 

You may also be interested in...



US FDA Vaccines Adcomm May Be Called To Review COVID-19 Vaccine Strain Changes

CBER Director Peter Marks said the VRBPAC may need to opine on the immunogenicity data gathered for vaccine updates.

Universal Flu Vaccine Is Still Several Years Away, Fauci Says

Developing a universal flu vaccine will be iterative process, National Institute of Allergy and Infectious Diseases Anthony Fauci says.

Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS122625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel